A smart precision inhaler for difficult-to-treat lung conditions
Lung disease remains one of the leading causes of death worldwide. Many promising new medicines, such as biologics, are fragile and hard to deliver to the lungs with today's inhalers, which produce droplets of varying size and leave much of the dose outside the diseased areas.
Gilbert is developing a next-generation soft mist inhaler based on its proprietary electrospray technology, which uses electric fields to atomize liquid medicine into droplets of exactly the same, adjustable size.
This allows high concentrations of a drug to be delivered gently and precisely to the diseased parts of the lungs. Gilbert partners with pharma and biotech companies to make their next generation of inhaled medicines possible, starting with difficult-to-treat conditions such as cystic fibrosis.
.webp)


